NeuroPace, Inc. (NASDAQ: NPCE) faces a regulatory delay after the U.S. Food and Drug Administration (FDA) determined that its Premarket Approval (PMA) Panel Track Supplement for the RNS System is not approvable in its current form. The supplemental application sought to expand the device’s labeled indication to include patients with antiseizure medication-resistant idiopathic generalized epilepsy (IGE). This decision halts the immediate path to broadening the addressable market, requiring NeuroPace to address specific agency concerns regarding data presentation and patient population context before the expansion can be considered.

Following the receipt of the FDA’s communication, NeuroPace held a meeting with the agency to discuss the feedback. At the FDA’s recommendation, the company will submit a Submission Issue Request (SIR) to further discuss its planned approach. Joel Becker, President and Chief Executive Officer of NeuroPace, stated that while disappointed with the lack of initial approval, management believes there is a clear path for approval through continued dialogue and the provision of additional information. The company intends to amend its submission with supplemental data from the NAUTILUS clinical trial.

Clinical Data Context

The PMA Supplement is supported by data from the NAUTILUS study, the first randomized controlled trial of neuromodulation in drug-resistant IGE. The 18-month results were published in Epilepsia in June 2026. Key findings include:

At 24 months, evaluable participants who received stimulation for 23 of 24 months achieved a median percent reduction in GTC seizures of 100% compared with baseline. Martha Morrell, MD, Chief Medical Officer of NeuroPace, noted that the average patient had lived with uncontrolled seizures for more than 18 years and was taking nearly 4 antiseizure medications daily. She emphasized that these patients are not candidates for epilepsy surgery and have no approved neuromodulation devices.

What the Numbers Show

The regulatory outcome highlights the stringent evidence standards for expanding indications into generalized epilepsy, where no surgical or neuromodulation treatments are currently approved. The FDA’s request for additional context suggests that while the efficacy signals—such as the 100% median reduction at 24 months—are strong, the initial submission may not have sufficiently differentiated the IGE cohort or addressed specific safety queries under the agency’s current review framework. Management guidance does not include any contribution from the expanded IGE indication in its current financial outlook. Investors should monitor the timing of the SIR submission and the subsequent Q2FY26 earnings call on August 11, 2026, for updates on the revised timeline.

Mizuho analyst Anthony Petrone has initiated coverage on NeuroPace with an Outperform rating and a price target of $22. The rating reflects a positive outlook on the company's performance.

Analyst Details

The coverage was initiated by Mizuho, targeting a price of $22 for NeuroPace shares.